The Effects of Leucine Metabolites in Performance, Body Composition and Biochemical Markers of Muscle Damage (LMET2IMPROVE)

February 21, 2024 updated by: Cristina Monteiro, Faculdade de Motricidade Humana

The Effects of β-hydroxy-β-methylbutyrate and Leucic Acid in Performance, Body Composition and Biochemical Markers

This study aimed to conduct a double-blind randomized pragmatic trial to evaluate the effects of off-the-shelf leucine metabolite supplements HMB-FA, HMB-Ca, alfa-HICA, on resistance training-induced changes in body composition, performance and biochemical markers of muscle damage. The investigators' working hypothesis is that so long as subjects adhered to a diet containing adequate energy and dietary protein, there would be no differences between those receiving the leucine metabolites - HMB-FA, HMB-Ca and alfa-HICA - when compared to a placebo consuming group.

Study Overview

Detailed Description

This was a randomized, double blind, placebo-controlled study with additional control of diet. The investigators compared the effect of 8 weeks of supplementation with HMB-FA, HMB-Ca, or alfa-HICA on performance, body composition, and biochemical markers of muscle damage. The study involved fifty-three participants engaged in resistance training for at least one year (≥3 training sessions per week).

Performance measures - To evaluate aerobic performance an incremental test to volitional exhaustion was performed. Peak power and strength was assessed by maximum strength and the participants also performed a Wingate and vertical jump tests. Perceived performance and recovery was measured by the perceived recovery status scores in training days. This tool allowed to evaluate both fatigue, general muscle soreness, sleep quality, stress levels and mood throughout the study. Performance tests were performed at baseline, prior to the beginning of the study, and at the end of weeks 4 and 8, in a fed state (a meal replacement bar was provided to participants before the tests).

Body composition measures - To evaluate body composition a dual-energy X-ray absorptiometry (DXA) scan was performed; Muscle thickness was measured by ultrasonography; Total body water and both the extracellular water and intracellular water were assessed by bioelectrical impedance spectroscopy (BIS). These tests were performed at baseline and at the end of weeks 4 and 8, with participants reporting to the lab in a fasted state, refraining from exercise, alcohol or stimulant beverages for at least 8 h.

Biochemical markers of muscle damage - To assess biochemical markers (total testosterone and cortisol, creatine kinase, insulin-like growth factor 1, growth hormone), blood was collected at baseline and at the end of weeks 4 and 8, in a fasted state with participants also refraining from exercise, alcohol or stimulant beverages for at least 12 h.

Training protocol - The training program was designed according to the guidelines for hypertrophy type of resistance training for intermediate-trained individuals and consisted on 3 sessions per week during an 8-week period.

Statistics - sample size was calculated through an a priori power analysis (G*Power Version 3.1.9.2, Heinrich Heine Universitat Dusseldorf, Germany), based on FFM changes from previous studies and power of 0.80. Statistical analysis will be performed using IBM SPSS statistics version 22.0 (IBM, Chicago, Illinois, USA). Normality of the distribution of variables will be tested by Shapiro-Wilk test. Baseline characteristics between groups were analyzed by a 1-way analysis of variance (ANOVA) since normality was observed. Time and time x group interactions will be evaluated by repeated-measures ANOVA. The equality of the matrix of variance and sphericity will be explored with the Levene F test and Mauchly's test, respectively. Overall significance level for α was set at p ≤ 0.05.

Study Type

Interventional

Enrollment (Actual)

53

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lisbon, Portugal, 1495-002 Cruz-Quebrada
        • Faculty of Human Kinetics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 41 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Resistance training subjects for more than one year

Exclusion Criteria:

  • Individuals taking any type of drug, medicines or supplements that may enhance body composition or performance, 1 months prior to the research.
  • Smokers
  • Clinical diagnose of a disease that might compromise tolerance to the supplements or influence body composition and performance
  • More than 25% body fat
  • Individuals involved in similar research 3 months prior to the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Experimental: HMB-FA
One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Experimental: HMB-Ca
One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Experimental: alfa-HICA
Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of maximum strength
Time Frame: Baseline, week 4 and week 8
kg
Baseline, week 4 and week 8
Change of peak power
Time Frame: Baseline, week 4 and week 8
Watt
Baseline, week 4 and week 8
Change of jump height
Time Frame: Baseline, week 4 and week 8
cm
Baseline, week 4 and week 8
Change of power
Time Frame: Baseline, week 4 and week 8
Watt
Baseline, week 4 and week 8
Change of muscle thickness
Time Frame: Baseline, week 4 and week 8
mm
Baseline, week 4 and week 8
Change of fat free mass
Time Frame: Baseline, week 4 and week 8
kg
Baseline, week 4 and week 8
Change of fat mass
Time Frame: Baseline, week 4 and week 8
Baseline, week 4 and week 8
Change of body water
Time Frame: Baseline, week 4 and week 8
kg
Baseline, week 4 and week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of biochemical markers of muscle damage
Time Frame: Baseline, week 4 and week 8
total testosterone and cortisol, creatine kinase, insulin-like growth factor 1, growth hormone
Baseline, week 4 and week 8
Oxygen uptake
Time Frame: Baseline and week 8
mL.kg-1.min-1
Baseline and week 8
Heart rate
Time Frame: Baseline and week 8
beats.min-1
Baseline and week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 29, 2017

Primary Completion (Actual)

October 28, 2017

Study Completion (Actual)

October 28, 2017

Study Registration Dates

First Submitted

April 2, 2018

First Submitted That Met QC Criteria

April 18, 2018

First Posted (Actual)

April 27, 2018

Study Record Updates

Last Update Posted (Estimated)

February 22, 2024

Last Update Submitted That Met QC Criteria

February 21, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • LabFisiolBioqMLeu

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Resistance Training

Clinical Trials on HMB-FA

Subscribe